This Mission Cancer topic supports pragmatic clinical trials aimed at improving immunotherapeutic interventions for patients with refractory cancers, focusing on effectiveness in real-world settings and evidence directly applicable to practice. The call text emphasizes randomised or cluster-randomised, academic investigator-initiated pragmatic trials that benefit patients with refractory cancers across stages, subtypes, age groups, and societal contexts. Endpoints should include overall survival and patient-reported outcomes/quality of life defined together with patients and caregivers/families.
Eligibility Criteria:
- Must submit an eligible proposal under this RIA topic and comply with Horizon Europe call conditions (see Work
- Programme and the Funding & Tenders Portal topic page).
- Proposal should include randomised or cluster-randomised academic investigator-initiated pragmatic clinical trials for patients with refractory cancers.
- Trial endpoints should target overall survival and patient-reported outcomes/quality of life important to patients and caregivers/families.
Funding Details:
- Action type: RIA.
- Total topic budget: €22.19M.
- Expected EU contribution per project: €7.00M–€8.00M.
- Indicative number of projects funded: 3.
Deadline:
- Deadline(s): 15 Sep 2026.
Where to go for further information: